Argenx Se · EURONEXT:ARGX
Argenx — J.P. Morgan Healthcare Conference 2026
26 slides from Argenx's conference presentation, Jan 15, 2026
Slide 1: Leading a new era of innovation in immunology
Leading a new era of innovation in immunology 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Patient testimonial: CIDP patient on VYVGART Hytrulo
“Before VYVGART Hytrulo I was struggling to walk to the end of the driveway, now I walk 10 miles a day. My activity level is where it was 10 years ago”* Sam, CIDP Patient *Individual patient outcome; does not necessarily reflect typical patient experience 3
Slide 4: Connecting Science and Patients to Unlock Infinite Opportunity
Connecting Science and Patients to Unlock Infinite Opportunity Science Patients 4
Slide 5: Our Innovation Engine is Powering Vision 2030
OUR I N N O VAT I O N ENGINE IS POWERING VISION 2030 50K Patients on Treatment 10 New Molecules in Phase 3 5 Labeled Indications 5
Slide 6: Our Innovation Engine is Powering Vision 2030 (19K patients)
OUR I N N O VAT I O N ENGINE IS POWERING VISION 2030 19K ~ Patients On VYVGART Globally 10 New Pipeline Molecules in 2025 4 Ongoing Registrational Studies 6
Slide 7: 2025 Product Net Sales of $4.2 Billion
2025 Product Net Sales of $4.2 Billion 1,286 1,127 Product net sales 90% (in millions of $) 949 YoY growth* FY 2025 FY 2024 G %* 790 4,151 2,186 +90% 737 Q4 2025 Q4 2024 G %* 573 1,286 737 +74% 478 374 398 Q4 2025 Q3 2025 G %* 329 269 1,286 1,127 +14% 218 173 131 75 2025: First Year of 21 Operating
Slide 8: 2026 Strategic Priorities
2026 Strategic Priorities Impact More Patients Shape Long-Term Deliver Next Wave with VYVGART Future of FcRn of Innovation Deliver broadest MG label First empa Phase 3 readout Advance combination (MMN) approaches AIM and ITP Phase 3 readouts 4 Phase 3 molecules 3 Clinical-stage FcRn Expand into rheu
Slide 9: Playbook to Reach 50K More Patients: Impact Patients with VYVGART
Playbook to Reach 50kMore Impact Patients Patients with VYVGART 9
Slide 10: Playbook for Indication Leadership with Precision Medicine
Playbook for Indication Leadership with Precision Medicine REDEFINE PATIENT OUTCOMES REDEFINE TREATMENT Patient Impact REDEFINE BIOLOGY Precision Approach New Standards Raise the Bar First-in-Class Commercial Excellence Combo/Multiple MoAs 10
Slide 11: Prefilled Syringe Launch is Increasing Patient Impact and Broadening Prescriber Base
Prefilled Syringe Launch is Increasing Patient Impact and Broadening Prescriber Base #1 PRESCRIBED BIOLOGIC MG EXPANSION VYVGART drove 70% Patients directly from orals 60% Growth in overall MG biologics share Earlier Line Patients NEW PRESCRIBER CIDP EXPANSION AND PATIENT GROWTH Achieved >4,700 Pre
Slide 12: Building Durable Leadership with the Broadest Label in MG
Building Durable Leadership with the Broadest Label in MG U.S. Addressable MG Patients +25K Redefine Patient Outcomes Launch in Seronegative MG* +7K Limited current treatment options Growth in Ocular MG Phase 3 Readout +11K Biologics Share of Market 60K First and only development in Ocular MG Empowe
Slide 13: Clear Path to CIDP Market Expansion
Clear Path to CIDP Market Expansion Redefine Treatment Evidence Generation ADHERE+ Functional Benefit HCP Prescriber Growth 42K Redefine Patient Outcomes 24K Biomarker Exploration IgG, IgM Autoantibodies 12K Progressing Multiple MOAs Addressable Total Treated Total Diagnosed Co-positioning VYVGART &
Slide 14: Building our Presence in Rheumatology
Building our Presence in Rheumatology Autoimmune Myositis Sjögren’s Disease PM Redefining Biology 10K MSAs1 linked to disease severity in IMNM; skin rash and treatment Anti-Ro/SSA and Anti-La/SSB IMNM response in DM are hallmarks of disease 20K 230K Redefining Treatment 70K Phase 2: Significant impr
Slide 15: Playbook to Reach 50K Patients: Shape the Long-term Future of FcRn
Playbook to Reach 50kthe Shape Patients Long-term Future of FcRn 15
Slide 16: Building a Sustainable FcRn Franchise
Building a Sustainable FcRn Franchise Diversified FcRn portfolio elevating the patient experience across IgG-mediated diseases Today Tomorrow Differentiated Efficacy and Patient Experience Enduring FcRn Leadership ARGX-213 ARGX-124 ARGX-XXX Phase 3 ready Phase 1 Future molecules FcRn Optimizing pati
Slide 17: Playbook to Reach 50K Patients: Deliver Next Wave of Innovation
Playbook to Reach 50k Patients Deliver Next Wave of Innovation 17
Slide 18: This will be a Pivotal Year for empasiprubart with First Phase 3 Readout in MMN
This will be a Pivotal Year for empasiprubart with First Phase 3 Readout in MMN 12k patients Market in MMN expected to grow MMN across key markets beyond $1B by 2030 Unmet Need 40% 0 60% Initially Targeted Progression misdiagnosed treatments despite treatment Future $1B+ Today Disease Burden $750-80
Slide 19: Empasiprubart Sustained Improved Grip Strength in MMN
Empasiprubart Sustained Improved Grip Strength in MMN ARDA Phase 2 ARDA+ Open Label Grip strength change from baseline (kPA) 19
Slide 20: Transformative Potential Across Pipeline Programs
Transformative Potential Across Pipeline Programs Efgartigimod Empasiprubart Adimanebart ARGX-213 ARGX-121 First-in-class Potent C2 MuSK agonist FcRn: Sustained IgA Sweeping Fc Fragment sweeping antibody antibody IgG reduction Antibody 15+ 3+ 3+ 15+ 3+ Indications Indications Indications Potential i
Slide 21: Successfully Advancing Next Wave of Molecules
Successfully Advancing Next Wave of Molecules ARGX-213: Convenient Monthly Dose Achieved ARGX-121: Rapid and Total IgA Depletion IgG Change from baseline (%) IgA Change from baseline (%) IgA-targeting Fab Fc-ABDEGTM α-albumin Fc-ABDEGTM VHH 21
Slide 22: Three New Phase 1 Molecules in 2026
Three New Phase 1 Molecules in 2026 Expanding our Academic Research Centers Biopharma companies ecosystem of where we Immunology Labs Immunology pipelines source novel biology g erin gy e iolo B Nov ion in Pip roduct ap el P elin Innovation e Engine An B e tib st in Field ring ody Enginee Broadened
Slide 23: Innovation Model Generating World-Class Pipeline
Innovation Model Generating World-Class Pipeline IIP/Preclinical Phase 1 PoC Registrational Approved ARGX-118 (Galectin) AMR Seronegative ARGX-124 (FcRn) Scleroderma Ocular MG 25 ARGX-125 AIE ITP Active IIP TSP-101 (Fn14) DGF Graves’ Disease PROGRAMS programs ALS Sjogren’s Disease Other Spanning neu
Slide 24: 6 Registrational Readouts Over Next 24 Months
6 Registrational Readouts Over Next 24 Months Phase 3 Data Readouts EFGARTIGIMOD EMPASIPRUBART Ocular 1Q 2026 MMN 4Q 2026 Myositis 3Q 2026 ITP 4Q 2026 CIDP 2H 2027 Sjogren’s Disease 2H 2027 Decision on Approval AChR- gMG (MuSK+, LRP4+, triple seronegative) by end of 2026 24
Slide 25: argenx: Continuous Innovation Engine
25 | VYVGART — ARGX-213 — in FcRn A ership R G X -124 Lead tis – Sjogren’ s Disease – Graves | A Myosi IE – Sclero ITP | de P– rma – CID – AMR MG t — C2 | asiprubar Adi manebart Emp —M uSK ARGX-109 | ARGX-11 121 — 8 GX- — ARG AR X-125 IIP Programs line t pe uc Pi prod a i n Fi e l d i n g in o d y E
Slide 26: Attractive De-Risked Profile of Phase 3 Studies
Attractive De-Risked Profile of Phase 3 Studies Ocular MG Myositis MMN ITP Sjogren’s ADAPT ocular domain ALKIVIA EMPASSION ADVANCE Phase 3 IV data Proof of Concept Proof of Concept RHO and DAHLIAS Real world data Japan Proof of concept Real-world case reports Cumulative platelet count primary endpoi